Cancer
Researchers at the University of Texas MD Anderson Cancer Center have made a groundbreaking discovery in understanding how genetic disorders, such as sickle cell disease (SCD), affect cancer immunotherapy. According to a new report published in the journal Immunity, SCD alters the 3D genome architecture of CD8+ T cells, leading
Cancer
Researchers have made a significant breakthrough in the treatment of severe hemophilia B, a rare bleeding disorder, using adeno-associated virus (AAV)-mediated gene therapy. The study, conducted at the Royal Free Hospital in London, involved 10 men with severe hemophilia B who received a single intravenous infusion of the scAAV2/
Cancer
Researchers from the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University have made a significant breakthrough in treating gastric cancer. The team, led by Xiaoyan Mao, discovered that a novel nanoparticle platform targeting the SLC6A14 (ATB) transporter can effectively inhibit gastric cancer cell proliferation in
Cancer
Researchers from Kyungpook National University have developed a machine learning (ML)-based framework using clinical laboratory parameters to identify eligible participants for gastric cancer clinical trials. The framework, which was tested using electronic medical records from 11,592 patients with gastric cancer, achieved a high accuracy rate, reducing the workload
Cancer
Researchers at the University of Cambridge have identified key challenges facing nanomedicine in cancer treatment, highlighting the need for a re-examination of nanoparticle pharmacokinetics, optimization of dosing regimens, and solutions to antigen depletion to realize the full potential of nanomedicine. Despite recent advances in targeted drug delivery, clinical trials of
Cancer
Researchers at the Poznan University of Technology have made a breakthrough discovery in the field of cancer treatment, finding that bismuth selenide (BiSe) nanoparticles can be effective in targeting and killing cancer cells, with the potential to be developed into a new therapy for cancer treatment. According to the study,
Cancer
OS Therapies Inc. (NYSE-A: OSTX) is making significant progress in the fight against rare cancers, particularly osteosarcoma, with its lead candidate, OST-HER2, demonstrating statistically significant survival benefits in patients with recurrent fully resected lung metastatic osteosarcoma. The company's immunotherapy, designed to activate the immune system against HER2-expressing cancer
Cancer
Alligator Bioscience, a clinical-stage biotechnology company, has expressed its encouragement regarding Shanghai Henlius Biotech's dosing of the first patient in the global Phase 3 clinical trial of HLX22 in combination with trastuzumab and chemotherapy for HER2-positive metastatic gastric and gastroesophageal junction cancer in the United States. The HLX22
Cancer
Scientists at Islamic Azad University have made a significant discovery in the field of cancer treatment using MoS nanoflakes. According to a recent study published in Scientific Reports, researchers have created a nanocomposite that combines MoS nanoflakes with FeO nanoparticles, gold nanorods, and copper sulfide, which shows great potential in
Cancer
Researchers at the University of Texas MD Anderson Cancer Center conducted a retrospective study of 66 patients who underwent CAR-T therapy to examine the association between pre-CAR-T pulmonary function testing (PFT) and subsequent complications. The study found that higher lung function scores correlated with increased risk of cytokine release syndrome
Cancer
Adcentrx Therapeutics has announced that its antibody-drug conjugate, ADRX-0405, has received orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of patients with gastric cancer. The STEAP1-targeting ADC demonstrated favorable preclinical results, including pharmacokinetics, safety, and efficacy in animal models. The agent is currently being
Cancer
Researchers at Universite Paris Cite have made a significant discovery in the fight against prostate cancer, a leading cause of cancer-related deaths among men worldwide. According to a recent study, a targeted therapy using lipid nanoparticles (LNPs) decorated with an anti-prostate-specific membrane antigen (PSMA) nanobody has shown enhanced and specific
